Abstract:Countless expectations converge in the multidisciplinary endeavour for the search and development of effective and safe drugs in fighting cancer. Although they still embody a minority of the pharmacological agents currently in clinical use, metal-based complexes have great yet unexplored potential, which probably hides forthcoming anticancer drugs. Following the historical success of cisplatin and congeners, but also taking advantage of conventional chemotherapy limitations that emerged with applications in the clinic, the design and development of non-platinum metal-based chemotherapeutics, either as drugs or prodrugs, represents a rapidly evolving field wherein candidate compounds can be fine-tuned to access interactions with druggable biological targets. Moving in this direction, over the last few decades platinum family metals, e.g., ruthenium and palladium, have been largely proposed. Indeed, transition metals and molecular platforms where they originate are endowed with unique chemical and biological features based on, but not limited to, redox activity and coordination geometries, as well as ligand selection (including their inherent reactivity and bioactivity). Herein, current applications and progress in metal-based chemoth are reviewed. Converging on the recent literature, new attractive chemotherapeutics based on transition metals other than platinum—and their bioactivity and mechanisms of action—are examined and discussed. A special focus is committed to anticancer agents based on ruthenium, palladium, rhodium, and iridium, but also to gold derivatives, for which more experimental data are nowadays available. Next to platinum-based agents, ruthenium-based candidate drugs were the first to reach the stage of clinical evaluation in humans, opening new scenarios for the development of alternative chemotherapeutic options to treat cancer.

Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Metal-based Anticancer Chemotherapeutic Agents.

Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes

Metal N-heterocyclic Carbene Complexes As Potential Metallodrugs in Antitumor Therapy

The Therapeutic Potential in Cancer of Terpyridine‐Based Metal Complexes Featuring Group 11 Elements

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Recent Researches in Metal Supramolecular Complexes As Anticancer Agents.

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Oxidation states in metallocenes: A key mechanistic component in cancer alleviation

N-heterocyclic carbene-metal complexes as bio-organometallic antimicrobial and anticancer drugs, an update (2015-2020)

Recent Developments In Organometallic Supramolecular Complexes As Anticancer Drugs

Metal Complexes in Medicine: Design and Mechanism of Action

Review: Recent Advances and Future Development of Metal Complexes As Anticancer Agents

Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy

Metal-N-heterocyclic carbene complexes as anti-tumor agents

Transition metal complexes with tetradentate Schiff bases (N 2 O 2 ) obtained from salicylaldehyde: A review of their possible anticancer properties

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Zn(II)‐curcumin complexes‐based anticancer agents